MedTrace Logo

Multisystem Cell Therapy for Improvement of Urinary Continence

NCT03439527 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-11-03

No results posted yet for this study

Summary

The rising success of cell therapies places an increasing burden on health care costs. Consequently, the need to reduce production costs while maintaining quality has been widely acknowledged. In addition, the demand for high-quality products with an optimal safety profile is increasing. The proposed cell treatment is the first therapeutical option with the possibility to revert the underlying condition. The investigators expect that this healing response will be achieved with minimal side effects justifying the addional costs and complexity.

Conditions

  • Urinary Stress Incontinence

Interventions

OTHER

Muscle Precursor Cells (MPCs), ATMP

The advanced therapeutic investigational product, the MPCs, is a living, autologous cell-product isolated from a biopsy of the patient's own musculus soleus.

Sponsors & Collaborators

  • University Hospital Tuebingen

    collaborator OTHER

  • Salzburger Landeskliniken

    collaborator OTHER

  • University of Zurich

    lead OTHER

Principal Investigators

  • Daniel Eberli, Prof · University of Zurich

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-22
Primary Completion
2021-09-03
Completion
2021-10-21

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03439527 on ClinicalTrials.gov